Mogelijk gemaakt door 
Translate
Translate
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in December.
Piper Sandler 37th Annual Healthcare Conference
Date / Time: |
December 2nd, at 9:00 AM ET |
Format: |
Presentation & 1x1’s |
Location: |
New York, NY |
Oppenheimer Movers in Rare Disease Summit
Date / Time: |
December 11th, at 9:00 AM ET |
Format: |
Panel & 1x1’s |
Location: |
New York, NY |
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251124688603/en/
For Investors and Media Bryan Giraudo, Chief Financial Officer & Chief Operating Officer Gossamer Bio Investor Relations [email protected]
Source: Gossamer Bio, Inc.
